B
Bart L. Scott
Researcher at Fred Hutchinson Cancer Research Center
Publications - 223
Citations - 6359
Bart L. Scott is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 38, co-authored 191 publications receiving 5075 citations. Previous affiliations of Bart L. Scott include University of Washington Medical Center & Seattle Cancer Care Alliance.
Papers
More filters
Journal ArticleDOI
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott,Marcelo C. Pasquini,Brent R. Logan,Juan Wu,Steven M. Devine,David L. Porter,Richard T. Maziarz,Erica D. Warlick,Hugo F. Fernandez,Edwin P. Alyea,Mehdi Hamadani,Asad Bashey,Sergio Giralt,Nancy L. Geller,Eric S. Leifer,Jennifer Le-Rademacher,Adam Mendizabal,Mary M. Horowitz,H. Joachim Deeg,Mitchell E. Horwitz +19 more
TL;DR: RIC resulted in lower TRM but higher relapse rates compared withMAC, with a statistically significant advantage in RFS with MAC, and these data support the use of MAC as the standard of care for fit patients with acute myeloid leukemia or myelodysplastic syndromes.
Journal ArticleDOI
Comorbidity and Disease Status–Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation
Mohamed L. Sorror,Brenda M. Sandmaier,Barry E. Storer,Michael B. Maris,Frédéric Baron,David G. Maloney,Bart L. Scott,H. Joachim Deeg,Frederick R. Appelbaum,Rainer Storb +9 more
TL;DR: Patients with low comorbidity scores could be candidates for prospective randomized trials comparing nonmyeloablatives and myeloablative conditioning regardless of disease status, and novel antitumor agents combined with nonmyelablative HCT should be explored among patients with high comorbridity scores and advanced disease.
Journal ArticleDOI
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease
Christopher S. Hourigan,Laura W. Dillon,Gege Gui,Brent R. Logan,Mingwei Fei,Jack Ghannam,Yuesheng Li,Abel Licon,Edwin P. Alyea,Asad Bashey,H. Joachim Deeg,Steven M. Devine,Hugo F. Fernandez,Sergio Giralt,Mehdi Hamadani,Alan Howard,Richard T. Maziarz,David L. Porter,Bart L. Scott,Erica D. Warlick,Marcelo C. Pasquini,Mitchell E. Horwitz +21 more
TL;DR: Evidence is provided that MAC rather than RIC in patients with AML with genomic evidence of MRD before alloHCT can result in improved survival, and models of AML MRD also showed benefit for MAC over RIC for those who tested positive.
Journal ArticleDOI
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis
Bart L. Scott,Brenda M. Sandmaier,Brenda M. Sandmaier,Barry E. Storer,Barry E. Storer,Michael B. Maris,Michael B. Maris,Mohamed L. Sorror,Mohamed L. Sorror,D.G. Maloney,D.G. Maloney,T. Chauncey,T. Chauncey,R Storb,R Storb,Deeg Hj,Deeg Hj +16 more
TL;DR: Graft vs leukemia effects may be more important than conditioning intensity in preventing progression in patients in chemotherapy-induced remissions at the time of transplantation.
Journal ArticleDOI
Hematopoietic Cell Transplantation as Curative Therapy for Idiopathic Myelofibrosis, Advanced Polycythemia Vera, and Essential Thrombocythemia
Daniella M. B. Kerbauy,Ted Gooley,George E. Sale,Mary E.D. Flowers,Kristine Doney,George E. Georges,Joanne E. Greene,Michael L. Linenberger,Effie W. Petersdorf,Brenda M. Sandmaier,Bart L. Scott,Mohamed L. Sorror,Derek L. Stirewalt,F. Marc Stewart,Robert P. Witherspoon,Rainer Storb,Frederick R. Appelbaum,H. Joachim Deeg +17 more
TL;DR: The findings show that hematopoietic cell transplantation offers potentially curative treatment for patients with ICMF, PV, or ET, and patients conditioned with targeted BU (plasma levels 800-900 ng/mL) plus cyclophosphamide (tBUCY) had a higher probability of survival than other patients.